SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A fair growth of 17.34% in the revenue at Rs. 41431.50 millions was reported in the September 2021 quarter as compared to Rs. 35309.70 millions during year-ago period.Net Profit for the quarter ended September 2021 zoomed to 261.68% from Rs. 2237.00 millions to Rs. 8090.70  millions.OP of the company witnessed a marginal growth to 11485.40 millions from 5228.70 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 41431.50 35309.70 17.34 74691.00 64940.10 15.02 128032.10 125319.30 2.16
Other Income 2842.70 835.60 240.20 4833.90 1608.90 200.45 1502.20 15109.20 -90.06
PBIDT 11485.40 5228.70 119.66 18378.30 12660.80 45.16 30862.20 42225.70 -26.91
Interest 1039.80 161.30 544.64 2097.00 850.30 146.62 2569.80 4080.10 -37.02
PBDT 10445.60 5067.40 106.13 16281.30 11810.50 37.85 27396.80 38145.60 -28.18
Depreciation 3336.40 3059.70 9.04 4845.60 4487.60 7.98 5868.10 5615.60 4.50
PBT 7109.20 2007.70 254.10 11435.70 7322.90 56.16 21528.70 32530.00 -33.82
TAX -981.50 -229.30 328.04 -848.00 -233.60 263.01 131.70 418.60 -68.54
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 8090.70 2237.00 261.68 12283.70 7556.50 62.56 21397.00 32111.40 -33.37
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 27.72 14.81 87.20 24.61 19.50 26.21 24.11 33.69 -28.46

Sun Pharma Inds. Share Price

1679.85 10.65 (0.64%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×